




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/62, 241/24, 279/12, 211/60, 211/90, A61K 31/445		A1	(11) International Publication Number: WO 98/34918
			(43) International Publication Date: 13 August 1998 (13.08.98)
(21) International Application Number: PCT/IB98/00064 (22) International Filing Date: 16 January 1998 (16.01.98) (30) Priority Data: 60/037,600 11 February 1997 (11.02.97) US (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): McCLURE, Kim, Francis [US/US]; Apartment #4, 6 School Street, Mystic, CT 06355 (US). (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES



(57) Abstract

A compound of formula (I) wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES

Background of the Invention

The present invention relates to arylsulfonyl hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (hereinafter NSAID'S) and analgesics for the treatment of arthritis, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, in the treatment of cancer.

This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to pharmaceutical compositions useful therefor.


There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalloproteases. Matrix-degrading metalloproteinases, such as gelatinase, stromelysin and collagenase, are involved in tissue matrix degradation (e.g. collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. corneal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Paget's disease and osteoporosis), tumor metastasis or invasion, as well as HIV-infection (J. Leuk. Biol., 52 (2): 244-248, 1992).

Tumor necrosis factor is recognized to be involved in many infectious and autoimmune diseases (W. Fiers, FEBS Letters, 1991, 285, 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al., Clinical Immunology and Immunopathology, 1992, 62 S11).

-2-

Summary of the Invention

The present invention relates to a compound of the formula



or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

15 X is carbon, oxygen or sulfur;

Y is carbon, oxygen, sulfur, SO, SO₂ or nitrogen;

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are selected from the group consisting of hydrogen, (C₁-C₈)alkyl optionally substituted by one or two groups selected from (C₁-C₈)alkylthio, (C₁-C₈)alkoxy, trifluoromethyl, halo, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arythio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarythio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₈)cycloalkyl, hydroxy, piperazinyl, (C₆-C₁₀)aryl(C₁-C₈)alkoxy, (C₅-C₉)heteroaryl(C₁-C₈)alkoxy, (C₁-C₈)acylamino, (C₁-C₈)acythio, (C₁-C₈)acyloxy, (C₁-C₈)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₈)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₈)alkylamino or ((C₁-C₈)alkylamino)₂; (C₂-C₈)alkenyl, (C₆-C₁₀)aryl(C₂-C₈)alkenyl, (C₅-C₉)heteroaryl(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₆-C₁₀)aryl(C₂-C₈)alkynyl, (C₅-C₉)heteroaryl(C₂-C₈)alkynyl, (C₁-C₈)alkylamino, (C₁-C₈)alkylthio, (C₁-C₈)alkoxy, perfluoro(C₁-C₈)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arythio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarythio, (C₅-C₉)heteroaryloxy, (C₃-C₈)cycloalkyl, (C₁-C₈)alkyl(hydroxymethylene), piperidyl, (C₁-C₈)alkylpiperidyl, (C₁-C₈)acylamino, (C₁-C₈)acythio, (C₁-C₈)acyloxy, R¹⁰(C₁-C₈)alkyl wherein R¹⁰ is (C₁-C₈)acylpiperazino, (C₆-C₁₀)arylpiperazino, (C₅-C₉)heteroarylpiperazino, (C₁-C₈)alkylpiperazino, (C₆-C₁₀)aryl(C₁-C₈)alkylpiperazino, (C₅-C₉)heteroaryl(C₁-C₈)alkylpiperazino, morpholino, thiomorpholino,

20


25

30

-3-

pyrrolidino, piperidyl, (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)aryl piperidyl, (C₅-C₉)heteroaryl piperidyl, (C₁-C₆)alkyl piperidyl (C₁-C₆)alkyl (C₆-C₁₀)aryl piperidyl (C₁-C₆)alkyl, (C₅-C₉)heteroaryl piperidyl (C₁-C₆)alkyl or (C₁-C₆)acylpiperidyl;

or a group of the formula




wherein n is 0 to 6;

y is 0 or 1;

W is oxygen or NR²⁴ wherein R²⁴ is hydrogen or (C₁-C₆)alkyl;


15 Z is OR¹¹ or NR²⁴R¹¹ wherein R²⁴ is as defined above and R¹¹ is as defined below; azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or a bridged diazabicycloalkyl ring selected from the group consisting of




30

-4-

5



d



e

10

wherein r is 1, 2 or 3;

m is 1 or 2;

p is 0 or 1; and

wherein each heterocyclic group may optionally be substituted by one or two groups

15 selected from hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₁₀)acyl, (C₁-C₁₀)acyloxy, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₅-C₉)heteroaryl(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl, (C₁-C₆)acyloxy(C₁-C₆)alkyl, (C₁-C₆)alkylthio, (C₁-C₆)alkylthio(C₁-C₆)alkyl, (C₆-C₁₀)arylthio, (C₆-C₁₀)arylthio(C₁-C₆)alkyl, R¹²R¹³N, R¹²R¹³NSO₂, R¹²R¹³NCO, R¹²R¹³NCO(C₁-C₆)alkyl wherein R¹² and R¹³ are each

20 independently hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)aryl (C₁-C₆)alkyl or (C₅-C₉)heteroaryl (C₁-C₆)alkyl or R¹² and R¹³ may be taken together with the nitrogen to which they are attached to form an azetidiny, pyrrolidiny, piperidiny, morpholiny or thiomorpholiny ring; R¹⁴SO₂, R¹⁴SO₂NH wherein R¹⁴ is trifluoromethyl, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl or (C₅-C₉)heteroaryl

25 (C₁-C₆)alkyl; R¹⁵CONR¹² wherein R¹² is as defined above and R¹⁵ is hydrogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₁-C₆)aryl(C₁-C₆)alkyl(C₆-C₁₀)aryl(C₁-C₆)alkoxy or (C₅-C₉)heteroaryl(C₁-C₆)alkyl; R¹⁶OOC, R¹⁶OOC(C₁-C₆)alkyl wherein R¹⁶ is (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)aryl (C₁-C₆)alkyl, 5-indany, CHR¹⁷OCOR¹⁸ wherein R¹⁷ is hydrogen or (C₁-C₆)alkyl and R¹⁸ is (C₁-C₆)alkyl,

30 (C₁-C₆)alkoxy or (C₆-C₁₀)aryl; CH₂CONR¹⁹R²⁰ wherein R¹⁹ and R²⁰ are each independently hydrogen or (C₁-C₆)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidiny, pyrrolidiny, piperidiny, morpholiny or


-5-

thiomorpholinyl ring; or $R^{21}O$ (C_1-C_6)alkyl wherein R^{21} is $H_2N(CHR^{22})CO$ wherein R^{22} is the side chain of a natural D- or L-amino acid;

R^{11} is hydrogen, (C_6-C_{10})aryl, (C_5-C_9)heteroaryl, (C_6-C_{10})aryl(C_1-C_6)alkyl, (C_5-C_9)heteroaryl(C_1-C_6)alkyl, (C_1-C_6)alkyl(C_6-C_{10})aryl(C_1-C_6)alkyl, (C_1-C_6)alkyl(C_5-C_9)heteroaryl(C_1-C_6)alkyl, 5-indanyl, $CHR^{17}OCOR^{18}$ or $CH_2CONR^{19}R^{20}$ wherein R^{17} , R^{18} , R^{19} and R^{20} are as defined above;

or R^1 and R^2 , or R^3 and R^4 , or R^5 and R^6 may be taken together to form a carbonyl;

or R^1 and R^2 , or R^3 and R^4 , or R^5 and R^6 , or R^7 and R^8 may be taken together to form a (C_3-C_6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula



wherein R^{23} is hydrogen, (C_1-C_6)acyl, (C_1-C_6)alkyl, (C_6-C_{10})aryl(C_1-C_6)alkyl, (C_5-C_9)heteroaryl(C_1-C_6)alkyl or (C_1-C_6)alkylsulfonyl; and

Q is (C_1-C_{10})alkyl, (C_6-C_{10})aryl, (C_6-C_{10})aryloxy(C_6-C_{10})aryl, (C_6-C_{10})aryl(C_6-C_{10})aryl, (C_6-C_{10})aryl(C_5-C_{10})aryl(C_1-C_6)alkyl, (C_6-C_{10})aryl(C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_6-C_{10})aryloxy(C_5-C_9)heteroaryl, (C_5-C_9)heteroaryl, (C_1-C_6)alkyl(C_6-C_{10})aryl, (C_1-C_6)alkoxy(C_6-C_{10})aryl, (C_6-C_{10})aryl(C_1-C_6)alkoxy(C_6-C_{10})aryl, (C_5-C_9)heteroaryloxy(C_6-C_{10})aryl, (C_1-C_6)alkyl(C_5-C_9)heteroaryl, (C_1-C_6)alkoxy(C_5-C_9)heteroaryl, (C_6-C_{10})aryl(C_1-C_6)alkoxy(C_5-C_9)heteroaryl, (C_5-C_9)heteroaryloxy(C_5-C_9)heteroaryl, (C_6-C_{10})aryloxy(C_1-C_6)alkyl, (C_5-C_9)heteroaryloxy(C_1-C_6)alkyl, (C_1-C_6)alkyl(C_6-C_{10})aryloxy(C_6-C_{10})aryl, (C_1-C_6)alkyl(C_5-C_9)heteroaryloxy(C_6-C_{10})aryl, (C_1-C_6)alkoxy(C_6-C_{10})aryloxy(C_6-C_{10})aryl, (C_1-C_6)alkoxy(C_5-C_9)heteroaryloxy(C_6-C_{10})aryl or (C_1-C_6)alkoxy(C_6-C_{10})aryloxy(C_5-C_9)heteroaryl optionally substituted by fluoro, chloro, (C_1-C_6)alkyl, (C_1-C_6)alkoxy or perfluoro(C_1-C_3)alkyl;

with the proviso that Z must be substituted when defined as azetidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl, (C_1-C_{10})acylpiperazinyl, (C_1-C_6)alkylpiperazinyl, (C_6-C_{10})aryl piperazinyl, (C_5-C_9)heteroaryl piperazinyl or a bridged diazabicycloalkyl ring;

-6-

with the proviso that R^7 is other than hydrogen only when R^8 is other than hydrogen;

with the proviso that R^6 is other than hydrogen only when R^5 is other than hydrogen;

5 with the proviso that R^3 is other than hydrogen only when R^4 is other than hydrogen;

with the proviso that R^2 is other than hydrogen only when R^1 is other than hydrogen;

10 with the proviso that when R^1 , R^2 and R^3 are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions;

with the proviso that when X is nitrogen, R^4 is not present;

with the proviso that when X is oxygen, sulfur, SO, SO_2 or nitrogen and when one or more of the group consisting of R^1 , R^2 , R^5 and R^6 , is a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 4- or 6- positions;

15 with the proviso that when Y is oxygen, sulfur, SO, SO_2 or nitrogen and when one or more of the group consisting of R^3 , R^4 , R^7 and R^8 , are independently a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 3- or 5- positions;

20 with the proviso that when X is oxygen, sulfur, SO or SO_2 , R^3 and R^4 are not present;

with the proviso that when y is 1 and W is NR^{24} or oxygen, Z cannot be hydroxy;

with the proviso that when Y is oxygen, sulfur, SO or SO_2 , R^5 and R^6 are not present;

with the proviso that when Y is nitrogen, R^6 is not present;

25 with the proviso that when the broken line represents a double bond, R^4 and R^6 are not present;

with the proviso that when R^3 and R^5 are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y;

30 with the proviso that when either the X or Y position is oxygen, sulfur, SO, SO_2 or nitrogen, the other of X or Y is carbon;

with the proviso that when X or Y is defined by a heteroatom, the broken line does not represent a double bond;

-7-

with the proviso that at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ must be defined as the group of formula II.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is defined above.

The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluoro, chloro, cyano, nitro, trifluoromethyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.

The term "heteroaryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents independently selected from the group consisting of fluoro, chloro, trifluoromethyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.


The term "acyl", as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy (such as methyloxy carbonyl), aryl, arylalkyl or arylalkyloxy and the terms "alkyl" or "aryl" are as defined above.

The term "acyloxy", as used herein, includes O-acyl groups wherein "acyl" is defined above.

The term "D- or L-amino acid", as used herein, unless otherwise indicated, includes glycine, alanine, valine, leucine, isoleucine, phenylalanine, asparagine, glutamine, tryptophan, proline, serine, threonine, tyrosine, hydroxyproline, cysteine, cystine, methionine, aspartic acid, glutamic acid, lysine, arginine or histidine.

The positions on the ring of formula I, as used herein, are defined as follows:

-8-



5

The preferred conformation of the compound of formula I includes hydroxamic acid axially disposed in the 2-position.

The compound of formula I may have chiral centers and therefore exist in 10 different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.

Preferred compounds of formula I include those wherein Y is carbon.

Other preferred compounds of formula I include those wherein Q is (C₁-C₈)alkoxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₈)alkoxy(C₆-C₁₀)aryl, or (C₆-C₁₀)aryl(C₁-C₈)alkoxy(C₁-C₈)alkyl wherein each terminal aryl group is optionally substituted by 15 fluoro.

Other preferred compounds of formula I include those wherein R², R³, R⁶, R⁷ and R⁹ are hydrogen.

More preferred compounds of formula I include those wherein Y is carbon; Q 20 is (C₁-C₈)alkoxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₈)alkoxy(C₆-C₁₀)aryl, or (C₆-C₁₀)aryl(C₁-C₈)alkoxy(C₁-C₈)alkyl.

Specific preferred compounds of formula I include the following:

(2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid;

25 (2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester;

(2R,4R)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid;

(2R,4R)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester;

30 (2R,3S)-{1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl}-carbamic acid isopropyl ester;

3-(S)-4-(4'-Fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

3-(S)-4-[4-(4-Fluorobenzyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

5 (2R,4S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide; and

(2R,4R)-1-(4-Methoxybenzenesulfonyl)-4-(piperazine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide hydrochloride.

Other compounds of the invention include:

10 (3S)-4-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

(3S)-2,2-Dimethyl-4-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;

(3S)-2,2-Dimethyl-4-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;

15 (3S)-4-[4-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

(3S)-2,2-Dimethyl-4-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;

20 (3S)-4-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

(3S)-2,2-Dimethyl-4-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;

(3S)-2,2-Dimethyl-4-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide;

25 (2R,3S)-{1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl}-carbamic acid methyl ester;

(2R,3S)-{2-Hydroxycarbamoyl-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic acid methyl ester;

30 (2R,3S)-{2-Hydroxycarbamoyl-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic acid methyl ester;

(2R,3S)-{1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl}-carbamic acid methyl ester;

- (2R,3S)-(1-{4-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl}-2-hydroxycarbamoyl-piperidin-3-yl)-carbamic acid methyl ester;
- (2R,3S)-{2-Hydroxycarbamoyl-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic acid methyl ester;
- 5 (2R,3S)-{1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl}-carbamic acid methyl ester;
- (2R,3S)-{2-Hydroxycarbamoyl-1-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic acid methyl ester;
- (2R,3S)-{2-Hydroxycarbamoyl-1-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic acid methyl ester;
- 10 (2R,3S)-1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-3-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-3-Hydroxy-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- 15 (2R,3S)-3-Hydroxy-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-3-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-1-[4-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl]-3-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- 20 (2R,3S)-3-Hydroxy-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-3-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- 25 (2R,3S)-3-Hydroxy-1-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-3-Hydroxy-1-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic acid hydroxyamide;
- 30 (2R,3S)-3-Hydroxy-3-methyl-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;

- (2R,3S)-3-Hydroxy-3-methyl-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-1-[4-(4-Fluorobenzoyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic acid hydroxyamide;
- 5 (2R,3S)-1-[4-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-3-Hydroxy-3-methyl-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-3-hydroxy-3-methyl-10 piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-3-Hydroxy-3-methyl-1-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-3-Hydroxy-3-methyl-1-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- 15 (3R)-4-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2,2-dimethyl-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-2,2-Dimethyl-4-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-2,2-Dimethyl-4-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-morpholine-3-20 carboxylic acid hydroxyamide;
- (3R)-4-[4-(4-Fluorobenzoyloxy)-benzenesulfonyl]-2,2-dimethyl-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-4-[4-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl]-2,2-dimethyl-morpholine-3-carboxylic acid hydroxyamide;
- 25 (3R)-2,2-Dimethyl-4-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-4-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-2,2-dimethyl-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-2,2-Dimethyl-4-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;
- 30 (3R)-2,2-Dimethyl-4-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;

- (2R,4R)-1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid;
- (2R,4R)-2-Hydroxycarbamoyl-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid;
- 5 (2R,4R)-2-Hydroxycarbamoyl-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid;
- (2R,4R)-1-[4-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid;
- (2R,4R)-2-Hydroxycarbamoyl-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid;
- 10 (2R,4R)-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid;
- (2R,4R)-2-Hydroxycarbamoyl-1-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid;
- 15 (2R,4R)-2-Hydroxycarbamoyl-1-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid;
- (3R)-4-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-3-methyl-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-3-Methyl-4-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;
- 20 (3R)-3-Methyl-4-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-4-[4-(4-Fluorobenzoyloxy)-benzenesulfonyl]-3-methyl-morpholine-3-carboxylic acid hydroxyamide;
- 25 (3R)-4-[4-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl]-3-methyl-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-3-Methyl-4-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;
- (3R)-4-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-3-methyl-morpholine-3-carboxylic acid hydroxyamide;
- 30 (3R)-3-Methyl-4-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;

- (3R)-3-Methyl-4-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide;
- (2R)-1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2-methyl-3-oxo-piperidine-2-carboxylic acid hydroxyamide;
- 5 (2R)-2-Methyl-3-oxo-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R)-2-Methyl-3-oxo-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-methyl-3-oxo-piperidine-2-carboxylic acid hydroxyamide;
- 10 (2R)-1-[2-(4-Fluorophenyl)-ethoxy]-benzenesulfonyl]-2-methyl-3-oxo-piperidine-2-carboxylic acid hydroxyamide;
- (2R)-2-Methyl-3-oxo-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- 15 (2R)-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-2-methyl-3-oxo-piperidine-2-carboxylic acid hydroxyamide;
- (2R)-2-Methyl-3-oxo-1-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R)-2-Methyl-3-oxo-1-[4-(1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- 20 (2R,4S)-1-(4-Benzyloxy-benzenesulfonyl)-4-butylaminomethyl-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R,4S)-4-Butylaminomethyl-1-[4-(4-fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- 25 (2R,4S)-4-Benzylamino-1-(4-benzyloxy-benzenesulfonyl)-piperidine-2-carboxylic acid hydroxyamide;
- (2R,4S)-4-Benzylamino-1-[4-(4-fluorobenzyloxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide;
- (2R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-oxo-piperidine-2-carboxylic acid hydroxyamide;
- 30 (2R,4R)-1-(4-Benzyloxy-benzenesulfonyl)-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide;

- (2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-methyl-piperazine-2-carboxylic acid hydroxyamide;
- 5 (2R,5S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-5-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R,5S)-1-(4-Benzyloxy-benzenesulfonyl)-5-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R,5R)-1-(4-Benzyloxy-benzenesulfonyl)-5-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- 10 (2R,5R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-5-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R,3S)-1-(4-Benzyloxy-benzenesulfonyl)-3-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- 15 (2R,4S)-1-(4-Benzyloxy-benzenesulfonyl)-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- (2R,4S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide;
- 1-(4-Butoxy-benzenesulfonyl)-3-(morpholine-4-carbonyl)-piperidine-2-carboxylic acid hydroxyamide;
- 20 1-[4-(4-Fluoro-benzyloxy)-benzenesulfonyl]-3-(morpholine-4-carbonyl)-piperidine-2-carboxylic acid hydroxyamide;
- 1-[3-(Fluoro-benzyloxy)-propane-1-sulfonyl]-3-(morpholine-4-carbonyl)-piperidine-2-carboxylic acid hydroxymide;
- 25 1-(4-Butoxy-benzenesulfonyl)-3-(pyrrolidine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide;
- 1-[4-(4-Fluoro-benzyloxy)-benzenesulfonyl]-3-(pyrrolidine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide;
- 1-[3-(4-Fluoro-benzyloxy)-propane-1-sulfonyl]-3-(pyrrolidine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide; and
- 30 1-[4-(4-Fluoro-benzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid.

-15-

The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in such treatments and a pharmaceutically acceptable carrier.

The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.


The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, compounds of formula I may be used in combination with standard NSAID'S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition.

25



-16-

Detailed Description of the Invention

The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , n and Ar in the reaction Schemes and the discussion that follow are defined as above.


Preparation 1

XVI




VI

-17-

Preparation 2

XVIII



XVII




VI





25

30


-18-

Scheme 1


-19-

Scheme 2


-20-

Scheme 3

XII




XI



X


30

-21-

Scheme 4


XXII

1



XXI

2







XX

30

-22-


Scheme 4 continued

XX




30


-23-

Scheme 5

XXVI



XXV



XXIV


30

-24-

Scheme 5 continued


XXIV

3



XXIII


4



XIV


Preparation 1 refers to the preparation of intermediates of the formula VI. Compounds of the formula VI are converted to compounds of the formula I according to the methods of Scheme 1. The starting materials of formula XVI can be prepared according to methods well known to those of ordinary skill in the art.

- 5 In reaction 1 of Preparation 1, the compound of formula XVI is converted to the corresponding hydroxy ester compound of formula VI by first reacting XVI with an arylsulfonylhalide in the presence of triethylamine and an aprotic solvent, such as methylene chloride, tetrahydrofuran or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature. The compound so formed is further
10 reacted with a compound of the formula



- 15 wherein R²⁵ is carbobenzyloxy, (C₁-C₆)alkyl, benzyl, allyl or tert-butyl, in the presence of sodium hexamethyldisilazane and a tetrahydrofuran-dimethylformamide solvent mixture at a temperature between about -20°C to about 20°C, preferably about 0°C, to form the hydroxy ester compound of formula VI.

- Preparation 2 refers to an alternate method of preparing compounds of the
20 formula VI. The starting materials of formula XVIII can be prepared according to methods well known to those of ordinary skill in the art. In reaction 1 of Preparation 2, the amine compound of formula XVIII, wherein R²⁵ is as defined above, is converted to the corresponding arylsulfonyl amine compound of formula XVII by (1) reacting XVIII with an arylsulfonylhalide in the presence of triethylamine and an aprotic solvent, such
25 as methylene chloride, tetrahydrofuran, or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature, (2) reacting the compound so formed with a compound of the formula




30

in the presence of sodium hexamethyldisilazane and a tetrahydrofuran-dimethylformamide solvent mixture at a temperature between about -20°C to about 20°C, preferably about 0°C, and (3) further reacting the compound so formed with ozone in a methylene chloride-methanol solution at a temperature between about -90°C

-26-

to about -70°C, preferably about -78°C. The unstable ozonide compound so formed is then reacted with triphenylphosphine to form the arylsulfonyl amine compound of formula XVII. In Reaction 2 of Preparation 2, the arylsulfonyl amine compound of formula XVII is converted to the corresponding hydroxy ester compound of formula VI by reacting XVII with a compound of the formula



wherein W is lithium, magnesium, copper or chromium.

Scheme 1 refers to the preparation of compounds of the formula II, which are compounds of the formula I, wherein X and Y are carbon; R⁴, R⁶ and R⁷ are hydrogen; and the dashed line between X and Y is absent. In reaction 1 of Scheme 1, the compound of formula VI, wherein the R²⁵ protecting group is carbobenzyloxy, (C₁-C₆) alkyl, benzyl, allyl or tert-butyl, is converted to the corresponding morpholinone compound of formula V by lactonization and subsequent Claisen rearrangement of the compound of formula VI. The reaction is facilitated by the removal of the R²⁵ protecting group from the compound of formula VI and is carried out under conditions appropriate for that particular R²⁵ protecting group in use. Such conditions include: (a) treatment with hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where R²⁵ is carbobenzyloxy, (b) saponification where R²⁵ is lower alkyl, (c) hydrogenolysis where R²⁵ is benzyl, (d) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid, where R²⁵ is tert-butyl, or (e) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R²⁵ is allyl.

In reaction 2 of Scheme 1, the morpholinone compound of formula V is converted to the carboxylic acid compound of formula IV by reacting V with lithium hexamethyldisilazane in an aprotic solvent, such as tetrahydrofuran, at a temperature between about -90°C to about -70°C, preferably about -78°C. Trimethylsilyl chloride is then added to the reaction mixture and the solvent, tetrahydrofuran, is removed in vacuo and replaced with toluene. The resulting reaction mixture is heated to a temperature between about 100°C to about 120°C, preferably about 110°C, and treated with hydrochloric acid to form the carboxylic acid compound of formula IV.

In reaction 3 of Scheme 1, the carboxylic acid compound of formula IV is converted to the corresponding hydroxamic acid compound of formula III by treating IV with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenztriazole in a polar solvent, such as dimethylformamide, followed by the addition of hydroxylamine to the reaction mixture after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxylamine is preferably generated in situ from a salt form, such as hydroxylamine hydrochloride, in the presence of a base, such as N-methylmorpholine. Alternatively, a protected derivative of hydroxylamine or its salt form, where the hydroxyl group is protected as a tert-butyl, benzyl or allyl ether, may be used in the presence of (benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate and a base, such as N-methylmorpholine. Removal of the hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride. N,O-bis(4-methoxybenzyl)hydroxylamine may also be used as the protected hydroxylamine derivative where deprotection is achieved using a mixture of methanesulfonic acid and trifluoroacetic acid.

In reaction 4 of Scheme 1, the hydroxamic acid compound of formula III is converted, if desired, to the corresponding piperidine compound of formula II by treating III with hydrogen and a hydrogenation catalyst, such as a 10% palladium on carbon.

Scheme 2 refers to the preparation of compounds of the formula VII, which are compound of the formula I wherein Y is nitrogen; X is carbon; R¹, R², R³, R⁴, R⁷ and R⁸ are hydrogen, and R⁶ is absent. The starting materials of formula IX can be prepared according to methods well known to those of ordinary skill in the art. In reaction 1 of Scheme 2, the arylsulfonylpiperazine compound of formula IX, wherein R²⁶ is carbobenzyloxy, benzyl or carbobenzoyloxy, is converted to the compound of formula VIII by reacting IX with a protected derivative of hydroxylamine of the formula



wherein R²⁷ is tertbutyl, benzyl or allyl, in the presence of dicyclohexylcarbodiimide, dimethylaminopyridine and an aprotic solvent, such as methylene chloride. The R²⁶ protecting group is chosen such that it may be selectively removed in the presence of an without loss of the R²⁷ protecting group, therefore, R²⁶ cannot be the same as R²⁷.

Removal of the R^{26} protecting group from the compound of formula IX is carried out under conditions appropriate for that particular R^{26} protecting group in use. Such conditions include; (a) treatment with a hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where R^{26} is carbobenzyloxy, (b) hydrogenolysis where
5 R^{26} is benzyl or (c) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid where R^{26} is carbotertbutyloxy.

In reaction 2 of Scheme 2, the compound of formula VIII is converted to the corresponding hydroxamic acid compound of formula VII, wherein R^5 is hydrogen or (C_1-C_6) alkyl, by reacting, if desired, VIII with an alkylhalide when R^5 is (C_1-C_6) alkyl.
10 Subsequent removal of the R^{27} hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride.

15 Scheme 3 refers to the preparation of compounds of the formula X, which are compounds of the formula I wherein Y is nitrogen; X is carbon; R^2 , R^7 , R^8 and R^9 are hydrogen; R^3 and R^4 taken together are carbonyl; R^5 is hydrogen, and R^6 is absent. In reaction 1 of Scheme 3, the arylsulfonylamine compound of formula XII, wherein R^{28} is as defined above, is converted to the corresponding piperazine compound of formula
20 XI by reacting XII with a carbodiimide and a base, such as triethylamine. The compound of formula XI is further reacted to give the hydroxamic acid compound of formula X according to the procedure described above in reaction 3 of Scheme 1.

Scheme 4 refers to the preparation of compounds of the formula XIII. The starting materials of formula XVIII can be prepared according to methods well known
25 to those of ordinary skill in the art. Compounds of the formula XIII are compounds of the formula I wherein X is carbon, and the dotted line between X and Y is absent. In reaction 1 of Scheme 4, removal of the R^{28} protecting group and subsequent reductive amination of the compound of formula XXII, wherein Y is oxygen, sulfur or carbon, to give the corresponding imine compound of formula XXI is carried out under conditions
30 appropriate for that particular R^{28} protecting group in use. Such conditions include those used above for removal of the R^{26} protecting group in reaction 1 of Scheme 2.

In reaction 2 of Scheme 4, the imine compound of formula XXI is converted to the corresponding piperidine compound of formula XX by reacting XXI with a nucleophile of the formula R^2M wherein M is lithium, magnesium halide or cerium

halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, at a temperature between about -78°C to about 0°C, preferably about -70°C.

In reaction 3 of Scheme 4, the sulfonation of the piperidine compound of formula XX to given the corresponding arylsulfonylpiperidine compound of formula XIX is carried out by reacting XX with an arylsulfonylhalide in the presence of triethylamine and an aprotic solvent, such as methylene chloride, tetrahydrofuran or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature.

In reaction 4 of Scheme 4, the arylsulfonylpiperidine compound of formula XIX is converted to the hydroxamic acid compound of formula XIII according to the procedure described above in reaction 3 of Scheme 1.

Scheme 5 refers to the preparation of compounds of the formula XIV, which are compounds of formula I wherein Y is nitrogen, X is carbon, the dotted line between X and Y is absent, R⁵ is hydrogen and R⁶ is absent. In reaction 1 of Scheme 5, the compound of formula XXVI, wherein the R²⁹ and R³¹ protecting groups are each independently selected from the group consisting of carbobenzyloxy, benzyl and carbobenzyloxy and R³⁰ is carbobenzyloxy, (C₁-C₆)alkyl, benzyl, allyl or tert-butyl, is converted to the corresponding imine compound of formula XXV by the removal of the R²⁹ protecting group and subsequent reductive amination of the compound of formula XXVI. The R²⁹ protecting group is chosen such that it may be selectively removed in the presence of and without loss of the R³¹ protecting group. Removal of the R²⁹ protecting group from the compound of formula XXVI is carried out under conditions appropriate for that particular R²⁹ protecting group in use which will not affect the R³¹ protecting group. Such conditions include; (a) treatment with hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where R²⁹ is carbobenzyloxy and R³¹ is tert-butyl, (b) saponification where R²⁹ is (C₁-C₆)alkyl and R³¹ is tert-butyl, (c) hydrogenolysis where R²⁹ is benzyl and R³¹ is (C₁-C₆) alkyl or tert-butyl, (d) treatment with a strong acid such as trifluoroacetic acid or hydrochloric acid where R²⁹ is tert-butyl and R³¹ is (C₁-C₆)alkyl, benzyl or allyl, or (e) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R²⁹ is allyl and R³¹ is (C₁-C₆)alkyl, benzyl or tert-butyl. The R³⁰ protective group may be selected such that it is removed in the same reaction step as the R²⁹ protecting group.

In reaction 2 of Scheme 5, the imine compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with a nucleophile of the formula R^2M wherein M is lithium, magnesium halide or calcium halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, at a temperature between about -78°C to about 0°C , preferably about -70°C .

In reaction 3 of Scheme 5, the sulfonation of the piperidine compound of formula XXIV to give the corresponding arylsulfonylpiperidine compound of formula III is carried out according to the procedure described above in reaction 3 of Scheme 4.

In reaction 4 of Scheme 5, the arylsulfonylpiperidine compound of formula XXIII is converted to the hydroxamic acid compound of formula XIV by (1) removing the R^{30} , if needed, and R^{31} protecting groups from XXIII followed by (2) reacting XXIII according to the procedure described above in reaction 3 of Scheme 1. Removal of the R^{30} and R^{31} protecting groups from the compound of formula XXIII is carried out under conditions appropriate for that particular R^{30} and R^{31} protecting group in use. Such conditions include those used above for removal of the R^{25} protecting group in reaction 1 of Scheme 1.

Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methylammonium salts.

Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.

The ability of the compounds of formula I or their pharmaceutically acceptable salts (the compounds of the invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following *in vitro* assay tests.

Biological Assay

Inhibition of Human Collagenase (MMP-1)

Human recombinant collagenase is activated with trypsin using the following ratio: 10 μ g trypsin per 100 μ g of collagenase. The trypsin and collagenase are
5 incubated at room temperature for 10 minutes then a five fold excess (50 μ g/10 μ g trypsin) of soybean trypsin inhibitor is added.

10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme:

10 mM \longrightarrow 120 μ M \longrightarrow 12 μ M \longrightarrow 1.2 μ M \longrightarrow 0.12 μ M

10 Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.

15 Collagenase is diluted to 400 ng/ml and 25 μ l is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/ml.

Substrate (DNP-Pro-Gly-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 μ M in assay buffer. The assay is initiated by the addition of 50 μ l substrate per well of the microfluor plate to give a final
20 concentration of 10 μ M.

Fluorescence readings (360 nm excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours.

Fluorescence vs time is then plotted for both the blank and collagenase
25 containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC₅₀ values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor
30 fluorescence divided by fluorescence of collagenase alone x 100). IC₅₀'s are determined from the concentration of inhibitor that gives a signal that is 50% of the control.

If IC_{50} 's are reported to be $<0.03 \mu M$ then the inhibitors are assayed at concentrations of $0.3 \mu M$, $0.03 \mu M$, $0.03 \mu M$ and $0.003 \mu M$.

Inhibition of Gelatinase (MMP-2)

Inhibition of gelatinase activity is assayed using the Dnp-Pro- α -Gly-Cys(Me)-His-Ala-Lys(NMA)- NH_2 substrate ($10 \mu M$) under the same conditions as inhibition of human collagenase (MMP-1).

72kD gelatinase is activated with 1 mM APMA (p-aminophenyl mercuric acetate) for 15 hours at $4^\circ C$ and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give final concentrations in the assay of $30 \mu M$, $3 \mu M$, $0.3 \mu M$ and $0.03 \mu M$. Each concentration is done in triplicate.

Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours.

IC_{50} 's are determined as per inhibition of human collagenase (MMP-1). If IC_{50} 's are reported to be less than $0.03 \mu M$, then the inhibitors are assayed at final concentrations of $0.3 \mu M$, $0.03 \mu M$, $0.003 \mu M$ and $0.003 \mu M$.

Inhibition of Stromelysin Activity (MMP-3)

Inhibition of stromelysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., Spectrophotometric Assay for Vertebrate Collagenase, Anal. Biochem. 147, 437-440 (1985)). Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-Gly-SCH[CH₂CH(CH₃)₂]CO-Leu-Gly-OC₂H₅] yields a mercaptan fragment that can be monitored in the presence of Ellman's reagent.

Human recombinant prostromelysin is activated with trypsin using a ratio of 1 μ l of a 10 mg/ml trypsin stock per 26 μ g of stromelysin. The trypsin and stromelysin are incubated at $37^\circ C$ for 15 minutes followed by 10 μ l of 10 mg/ml soybean trypsin inhibitor for 10 minutes at $37^\circ C$ for 10 minutes at $37^\circ C$ to quench trypsin activity.

Assays are conducted in a total volume of 250 μ l of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter plates. Activated stromelysin is diluted in assay buffer to 25 μ g/ml. Ellman's reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 μ l per well yielding at 1 mM final concentration.

10 mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 μ L to the appropriate wells yields final

-33-

concentrations of 3 μ M, 0.3 μ M, 0.003 μ M, and 0.0003 μ M. All conditions are completed in triplicate.

A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 μ l to each well to give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman's reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader.

IC₅₀ values were determined in the same manner as for collagenase.

Inhibition of MMP-13

Human recombinant MMP-13 is activated with 2mM APMA (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5mM calcium chloride, 20 μ M zinc chloride, 0.02% brij). Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.

10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 μ M, 3 μ M, 0.3 μ M, and 0.03 μ M.

Substrate (Dnp-Pro-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is prepared as for inhibition of human collagenase (MMP-1) and 50 μ l is added to each well to give a final assay concentration of 10 μ M. Fluorescence readings (360 nm excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour.

Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.

IC₅₀'s are determined as per inhibition of human collagenase (MMP-1). If IC₅₀'s are reported to be less than 0.03 μ M, inhibitors are then assayed at final concentrations of 0.3 μ M, 0.03 μ M, 0.003 μ M and 0.0003 μ M.

Inhibition of TNF Production

The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following in vitro assay:

Human mononuclear cells were isolated from anti-coagulated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2×10^6 /ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations.

180 μ l of the cell suspension was aliquoted into flat bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 200 μ l. All conditions were performed in triplicate. After a four hour incubation at 37°C in an humidified CO₂ incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supernatants removed and assayed for TNF α using the R&D ELISA Kit.

For administration to mammals, including humans, for the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF), a variety of conventional routes may be used including orally, parenterally and topically. In general, the compound of the invention will be administered orally or parenterally at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

The compounds of the invention can be administered in a wide variety of different dosage forms. In general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight

polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. In the case of animals, they are advantageously contained in an animal feed or drinking water in a concentration of 5-5000 ppm, preferably 25 to 500 ppm.

For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to 3 divided doses.

The present invention is illustrated by the following examples, but it is not limited to the details thereof.

EXAMPLE 1

(2R, 4R)-1-(4-Methoxy-benzenesulfonyl)-4-(piperazine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide hydrochloride

(a) To a stirred, cold (-78 °C) solution of (2R)-2-benzyloxycarbonylamino-pentanedioic acid 1-tert-butyl ester 5-methyl ester (5.6g, 15.9 mmol), prepared as described in J. Org. Chem., 55, 1711-1721 (1990) and J. Med. Chem., 39, 73-85 (1996), in 30 mL of tetrahydrofuran was added lithium bis(trimethylsilyl)amide (40 mL, 1 M in tetrahydrofuran, 39.8 mmol). The resulting mixture was stirred for 1 hour at -45 °C and then recooled to -78 °C. Allyl bromide (5.2 mL, 63.7 mmol) was then added. After 2 hours the reaction was quenched by the addition of 1 M aqueous hydrogen chloride at -78 °C. The mixture was then extracted with diethyl ether. The combined ethereal

extracts were washed with brine and the mixture was dried over sodium sulfate. After filtration and concentration of the filtrate, the crude product was purified by silica gel chromatography (elution with 1:5 ethyl acetate/hexanes) to provide (2R,4R)-4-allyl-2-benzyloxycarbonylamino-pentanedioic acid 1-tert-butyl ester 5-methyl ester.

- 5 (b) Ozone gas was bubbled through a stirred, cold (-78 °C) solution of (2R,4R)-4-allyl-2-benzyloxycarbonylamino-pentanedioic acid 1-tert-butyl ester 5-methyl ester (5.0 g, 12.8 mmol) in 100 mL of 10:1 methanol/methylene chloride, and 0.73 mL of acetic acid until a blue color persisted. Nitrogen gas was then bubbled through the solution until the blue color dissipated. The mixture was warmed to ambient temperature and
10 dimethyl sulfide (2.8 mL, 3.83 mmol) was added. The mixture was stirred for 48 hours, diluted with methylene chloride, and washed with 10% aqueous sodium carbonate, brine, and the mixture was dried over sodium sulfate. Filtration and concentration of the filtrate provided (2R,4S)-6-methoxy-piperidine-1,2,4-tricarboxylic acid 1-benzyl ester 2-tert-butyl ester 4-methyl ester as a clear oil, which was used in the subsequent step
15 without purification.

- (c) A mixture of (2R,4S)-6-methoxy-piperidine-1,2,4-tricarboxylic acid 1-benzyl ester 2-tert-butyl ester 4-methyl ester (4.85 g, 11.9 mmol) and 10% palladium on carbon (500 mg) in 100 mL of ethanol was shaken under a 45 psi atmosphere of hydrogen gas for 1.5 hours. The mixture was filtered through nylon and the filtrate was concentrated to
20 provide (2R,4R)-piperidine-2,4-dicarboxylic acid 2-tert-butyl ester 4-methyl ester as light yellow oil, which was used in the subsequent step without further purification.

- (d) To a stirred, cold (0 °C) solution of (2R,4R)-piperidine-2,4-dicarboxylic acid 2-tert-butyl ester 4-methyl ester (2.7 g, 11.1 mmol) and triethylamine (4.6 mL, 33.3 mmol) in 30 mL of methylene chloride was added 4-methoxy-benzenesulfonyl chloride (2.3 g,
25 11.1 mmol). The mixture was warmed to ambient temperature and stirred for 4 hours. The reaction was quenched by the addition of aqueous ammonium chloride and the mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine, and the organic mixture was dried over sodium sulfate. After filtration and concentration of the filtrate, the resulting crude product was purified by silica gel
30 chromatography (elution with 3:8 ethyl acetate/hexanes) to provide (2R,4R)-1-(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxylic acid 2-tert-butyl ester 4-methyl ester.

-37-

- (e) To a stirred, cold (0 °C) solution of (2R,4R)-1-(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxylic acid 2-tert-butyl ester 4-methyl ester (4.4 g, 10.6 mmol) in 30 mL of methylene chloride was added 10 mL of trifluoroacetic acid dropwise. The mixture was stirred for 1 hour at 0 °C and for 8 hours at ambient temperature.
- 5 Concentration provided (2R,4R)-1-(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxylic acid 4-methyl ester, which was used in the subsequent step without purification.
- (f) To a stirred solution of (2R,4R)-1-(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxylic acid 4-methyl ester (4.4 g, 12.3 mmol), O-benzylhydroxylamine hydrochloride (2.15 g, 13.5 mmol), and triethylamine (5.15 mL, 36.9 mmol) was added benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (6.0 g, 12.3 mmol) at ambient temperature. The resulting mixture was stirred for 24 hours. The mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrogen chloride, aqueous sodium bicarbonate, and brine. The organic mixture was dried over
- 15 magnesium sulfate, filtered, and the filtrate was concentrated. The crude residue was purified by silica gel chromatography (elution with 5% methanol in methylene chloride) to provide (2R,4R)-2-benzyloxycarbamoyl-1-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid methyl ester as a colorless solid.
- (g) To a stirred cold (0 °C) solution of (2R,4R)-2-benzyloxycarbamoyl-1-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid methyl ester (4.0 g, 8.6 mmol) in 10 mL of 9:1 methanol/water was added lithium hydroxide monohydrate (1.8 g, 43 mmol). The mixture was stirred for 2 hours before Amberlite IR-120 resin (96 g) was added. After 15 minutes, the mixture was filtered and the filtrate was concentrated to give (2R,4R)-2-benzyloxycarbamoyl-1-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid, which
- 25 was used in the subsequent reaction without purification.
- (h) To a stirred solution of (2R,4R)-2-benzyloxycarbamoyl-1-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid (500 mg, 1.11 mmol), tert-butylloxycarbonyl piperazine (226 mg, 1.21 mmol), and triethylamine (0.47 mL, 3.33 mmol) was added benzotriazol-1-yloxy-tris(dimethylamino)phosphonium
- 30 hexafluorophosphate (535 mg, 1.21 mmol) at ambient temperature. The resulting mixture was stirred for 24 hours. The mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrogen chloride, aqueous sodium bicarbonate, and brine.

-38-

The organic mixture was dried over magnesium sulfate, filtered, and the filtrate was concentrated. The crude residue was purified by silica gel chromatography (elution with 2% methanol in methylene chloride) to provide (2R,4R)-4-[2-benzyloxycarbamoyl-1-(4-methoxy-benzenesulfonyl)-piperidine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester as a colorless solid.

(i) A mixture of (2R,4R)-4-[2-benzyloxycarbamoyl-1-(4-methoxy-benzene-sulfonyl)-piperidine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester (500 mg, 0.81 mmol) and 5% palladium on barium sulfate (250 mg) in 10 mL of methanol was shaken under a 40 psi atmosphere of hydrogen gas for 1.5 hours. Filtration through nylon and concentration of the filtrate provided (2R,4R)-4-[2-hydroxycarbamoyl-1-(4-methoxy-benzenesulfonyl)-piperidine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester as a colorless solid, which was used in the subsequent step without purification.

(j) Hydrogen chloride gas was bubbled through a cold (0°C) solution of (2R,4R)-4-[2-hydroxycarbamoyl-1-(4-methoxy-benzenesulfonyl)-piperidine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester (420 mg, 0.8 mmol) for 10 minutes. After an additional 20 minutes the mixture was concentrated to provide (2R, 4R)-1-(4-methoxy-benzenesulfonyl)-4-(piperazine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide hydrochloride as a colorless solid: Mass spectrum (atmospheric pressure chemical ionization; basic mode) m/z (M+H) 427, 366; ^1H NMR (dimethyl sulfoxide- d_6 , 400 MHz, ppm) δ 10.70 (bd, 1 H, J = 2.7 Hz), 9.06 (bs, 2 H), 8.84 (bs, 1 H), 7.70 (dd, 2 H, J = 8.9, 2.9 Hz), 7.06 (dd, 2 H, J = 8.9, 2.9 Hz), 4.42 (bs, 1 H), 3.80 (s, 3 H), 3.80-3.20 (m, 6 H), 3.04 (m, 4 H), 2.76 (m, 1 H), 1.79 (bd, 1 H, J = 13.5 Hz), 1.52 (bd, 1 H, J = 12.6 Hz), 1.32 (m, 1 H) 1.14 (m 1H).

Example 2

25 (2R,4R)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester

(a) To a stirred solution of (2R,4R)-piperidine-2,4-dicarboxylic acid 2-tert-butyl ester 4-methyl ester (920 mg, 3.78 mmol) and triethylamine (1.58ml, 11.3 mmol) in 10 mL of methylene chloride was added a solution of 3-(4-fluorophenoxy)-propane-1-sulfonyl chloride (1.05 g, 4.16 mmol) in 2 mL of methylene chloride under a nitrogen atmosphere. The mixture was stirred for 16 hours at ambient temperature (22 °C), then

diluted with 20 mL of 1 N hydrochloric acid and 20 mL of methylene chloride. The organic layer was removed and washed with brine and dried over sodium sulfate. Filtration and concentration of the filtrate gave 2.8 g of a yellow oil, which was purified by flash chromatography (3:2 hexanes/ethyl acetate elution) to give 1.15 g (2R,4R)-1-[3-(4-fluoro-phenoxy)-propane-1-sulfonyl]-piperidine-2,4-dicarboxylic acid 2-tert-butyl ester 4-methyl ester of as a yellow oil.

(b) To a stirred, cold (0 °C) solution of (2R,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-piperidine-2,4-dicarboxylic acid 2-tert-butyl ester 4-methyl ester (1.15 g, 2.5 mmol) in 10 mL of methylene chloride was added 10 mL of trifluoroacetic acid. The mixture was allowed warm to ambient temperature (22 °C) over 16 hours. The mixture was concentrated in vacuo to give 970 mg of crude (2R,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-piperidine-2,4-dicarboxylic acid 4-methyl ester as a orange solid.

(c) To a stirred solution of (2R,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-piperidine-2,4-dicarboxylic acid 4-methyl ester (970 mg, 2.4 mmol) in 5 mL of methylene chloride was added triethylamine (1.0 mL, 7.2 mmol) and O-benzylhydroxylamine hydrochloride (410 mg, 2.64 mmol) at ambient temperature (22 °C). To the resulting solution was added benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (1.17 g, 2.64 mmol) and the mixture was stirred for 16 hours under a nitrogen atmosphere. The mixture was diluted with 25 mL of 1 N hydrochloric acid and 25 mL of ethyl acetate. The organic layer was removed and the aqueous layer was extracted with ethyl acetate (2 x). The combined organic layers were washed with saturated aqueous sodium carbonate (1 x) and brine (1 x). The organic layer was dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo. Purification of the viscous yellow residue by flash chromatography (eluting with 1:1 ethyl acetate/hexanes) gave 810 mg of (2R,4R)-2-benzylloxycarbonyl-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-piperidine-4-carboxylic acid methyl ester as a clear oil.

(d) A mixture of (2R,4R)-2-benzylloxycarbonyl-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-piperidine-4-carboxylic acid methyl ester (800 mg, 1.57 mmol) and 200 mg of 5% palladium on barium sulfate in 15 mL of methanol was shaken in a Parr apparatus under a 40 psi hydrogen gas atmosphere for 2 hours. The catalyst was removed by passage of the mixture through a 0.45 µm nylon filter and the filtrate was concentrated to give 650 mg of (2R,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-2-

hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester as a white foam: MS (atmospheric pressure chemical ionization) acidic mode, 417 (M-1); ¹H NMR (400 MHz, CDCl₃) δ 6.94-6.97 (m, 2 H), 6.80-6.83 (m, 2 H), 4.56 (s, 1 H), 4.03 (t, 2 H, J = 5.3 Hz), 3.83 (d, 1 H, J = 12.9 Hz), 3.68 (s, 3 H), 3.15-3.28 (m, 3 H), 2.76 (t, 1 H, J = 11.5 Hz), 2.54 (d, 1 H, J = 13.5 Hz), 2.26 (d, 2 H, J = 5.9 Hz), 2.02 (m, 1 H, J = 13.0 Hz), 1.73-1.78 (m, 1 H), 1.56-1.62 (m, 1 H).

Example 3

(2R,4R)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid

10 To a stirred, cold (0 °C) solution of (2R,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester (400 mg, 0.96 mmol) in 5 mL of a methanol/water mixture (10:1) was added lithium hydroxide monohydrate (120 mg, 2.88 mmol). After 3 hours at 0 °C, prerinse (methanol) Amberlite resin (4.1g) was added. The mixture was filtered and the filtrate was
15 concentrated to give 370 mg of (2R,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid as a white foam: MS (atmospheric pressure chemical ionization) acidic mode, 403 (M-1).

Example 4

(2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester

20

4-(4-Fluoro-benzyloxy)-benzenesulfonyl chloride. MS: 465 (M-1).

The titled compound of example 4 was prepared by a method analogous to that described in example 2 using the reagents.

Example 5

(2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid. MS: 451 (M-1).

25

The titled compound of example 5 was prepared by a method analogous to that described in example 3 starting with 1-[4-(4-Fluoro-benzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester.

Example 62R,3S-(1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl)-carbamic acid isopropyl ester

(a) To a stirred, cold (0 °C) solution of the known (Agami, C.; Hamon, L.; Kadouri-Puchôt, C.; Le Guen, V *J. Org. Chem.* 1996, 61, 5736-5742) [4S-4 α ,9 α ,9 $\alpha\alpha$]-1-oxo-4-phenyl-octahydro-pyrido[2,1-c][1,4]oxazine-9-carboxylic acid methyl ester (8.28 g, 2.86 mmol) in 100 mL of tetrahydrofuran was added 2.39 mL of concentrated hydrochloric acid. After 5 minutes the mixture was concentrated to dryness. The resulting solid was suspended in ethyl acetate and the mixture was stirred for an hour. The solids were collected by filtration, rinsed with ethyl acetate, and dried to give 9.04 g of a white solid.

Two grams of this solid was dissolved in 26 mL of 6 N hydrochloric acid and heated at reflux for 6 hours. The mixture was cooled to 0 °C and neutralized with 3 N sodium hydroxide and concentrated in vacuo. The resulting solids were suspended in chloroform and passed through a 45 μ m nylon filter. The filtrate was concentrated to a yellow oil which was purified by flash chromatography (eluting with 2:1 hexanes/ethyl acetate with 1% acetic acid) to give 802 mg of [4S-4 α ,9 α ,9 $\alpha\alpha$]-1-oxo-4-phenyl-octahydro-pyrido[2,1-c][1,4]oxazine-9-carboxylic acid as white solid.

(b) To a stirred solution of [4S-4 α ,9 α ,9 $\alpha\alpha$]-1-oxo-4-phenyl-octahydro-pyrido[2,1-c][1,4]oxazine-9-carboxylic acid (568 mg, 2.06 mmol) in 15 mL of benzene was added triethylamine (0.28 mL, 2.06 mmol) and diphenylphosphoryl azide (0.44 mL, 2.06 mmol) at 22 °C under a nitrogen atmosphere. The mixture was stirred at 22 °C for 45 minutes and at reflux for 50 minutes before 2-propanol (3.2 mL, 41.2 mmol) was added. After an additional 20 hours at reflux the mixture was cooled to 22 °C and concentrated in vacuo. The residue was taken up in ethyl acetate and the resulting solution was washed with 5% citric acid, water, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo. The yellow residue was purified by flash chromatography (eluting with 3:1 hexanes/ethyl acetate) to give 402 mg of [4S-4 α ,9 α ,9 $\alpha\alpha$](1-oxo-4-phenyl-octahydro-pyrido[2,1-c][1,4]oxazin-9-yl)-carbamic acid isopropyl ester as white solid.

- (c) A mixture of [4S-4 α ,9 α ,9 $\alpha\alpha$](1-oxo-4-phenyl-octahydro-pyrido[2,1-c][1,4]oxazin-9-yl)-carbamic acid isopropyl ester (900 mg, 2.71 mmol) and 20% palladium hydroxide on carbon (920 mg) in 77 mL of ethanol/water (10:1) was shaken in a Parr apparatus under a 45 psi hydrogen gas atmosphere for 72 hours.
- 5 The catalyst was removed by passage of the mixture through a 0.45 μ m nylon filter and the filtrate was concentrated to give 610 mg of 2R,3S-3-isopropoxycarbonylamino-piperidine-2-carboxylic acid as white solid. MS: 229 (M-1).
- (d) To a stirred solution of 2R,3S-3-isopropoxycarbonylamino-piperidine-2-carboxylic acid (320 mg, 1.39 mmol) in 5 mL of methylene chloride was added
- 10 triethylamine (0.58 mL, 4.17 mmol) followed by 4-(4-fluorobenzyloxy)-benzenesulfonyl chloride (460 mg, 1.53 mmol). After 16 hours at 22 °C the mixture was partitioned between 1 N hydrochloric acid and ethyl acetate. The organic layer was removed and washed with brine and dried over sodium sulfate. Filtration and concentration of the filtrate gave 480 mg of crude 2R,3S-1-[4-(4-fluorobenzyloxy)-
- 15 benzenesulfonyl]-3-isopropoxycarbonylamino-piperidine-2-carboxylic acid as a light yellow solid.
- (e) To a stirred, cold (0 °C) solution of crude 2R,3S-1-[4-(4-fluorobenzyloxy)-benzenesulfonyl]-3-isopropoxycarbonylamino-piperidine-2-carboxylic acid (380 mg, 0.77 mmol) in 5 mL of methylene chloride was added
- 20 triethylamine (0.32 mL, 2.31 mmol) followed by benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (510 mg, 1.15 mmol). The resulting solution was stirred for 2 minutes at 0 °C under a nitrogen atmosphere before O-(trimethylsilylethyl)hydroxylamine hydrochloride (195 mg, 1.15 mmol) was added. The mixture was allowed to warm slowly to 22 °C over 14 hours. The
- 25 mixture was concentrated in vacuo and the residue was diluted with water and extracted with ethyl acetate/diethyl ether (1:1; 3 x). The combined organic extracts were washed with saturated aqueous carbonate (2 x), water (2 x), and brine (1 x). The organic layer was dried (magnesium sulfate), filtered, and the filtrate was concentrated in vacuo. The yellow residue was purified by flash chromatography
- 30 (eluting with 65:35 hexanes/ethyl acetate) to give 300 mg of 2R,3S-1-[4-(4-fluorobenzyloxy)-benzenesulfonyl]-2-(2-trimethylsilyl-ethoxycarbonyl)-piperidin-3-yl]-carbamic acid isopropyl ester as a white foam. MS: 610 (M+1).

-43-

(f) To a stirred, cold (0 °C) solution of 2R,3S-[1-[4-(4-fluorobenzyloxy)-benzenesulfonyl]-2-(2-trimethylsilyl-ethoxycarbonyl)-piperidin-3-yl]-carbamic acid isopropyl ester (265 mg, 0.44 mmol) in 4 mL of methylene chloride was added 3 mL of trifluoroacetic acid. The resulting colorless solution was allowed to warm to 23 °C over 2 hours and was stirred for an additional 28 hours. The mixture was concentrated in vacuo to a solid/foam, which was suspended in ethyl acetate hexanes (1:6) and stirred for 10 hours. The white solids were collected by filtration, rinsed with hexanes, and purified further by flash chromatography (eluting with 7:3 ethyl acetate/hexanes with 1% acetic acid) to give 130 mg of 2R,3S-1-[4-(4-fluorobenzyloxy)benzenesulfonyl]-2-hydroxycarbonyl-piperidin-3-yl]-carbamic acid isopropyl ester as a white solid/foam. MS: 510 (M+1).

Example 7

3-(S)-4-(4'-Fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide

(a) To a stirred solution of the known (PCT Publication WO 97/20824) 3-(S)-dimethylthexylsilyl-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxylate (1.17 g, 3.70 mmol) in 6 mL of methylene chloride was added triethylamine (1.02 mL, 7.40 mmol) followed by 4'-fluorobiphenylsulfonyl chloride (1.0 g, 3.70 mmol). The resulting solution was stirred for 56 hours at 23 °C. The reaction mixture was diluted with methylene chloride and washed with water. The organic layer was concentrated in vacuo; the residue was dissolved in methanol, and the mixture was heated at reflux for 6 hours. The mixture was cooled to 23 °C and concentrated in vacuo. The residue was purified by flash chromatography (eluting with 3:7 ethyl acetate/hexanes with 0.1% acetic acid) to give 670 mg of 3-(S)-4-(4'-fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid as a white foam/solid. MS: 427 (M+NH₄).

(b) To a stirred, cold (0 °C) solution of 3-(S)-4-(4'-fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid (605 mg, 1.48 mmol) in 5 mL of methylene chloride was added triethylamine (0.62 mL, 4.43 mmol) under a nitrogen atmosphere. Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (980 mg, 2.22 mmol) was added and the resulting solution was stirred for 5 minutes before O-(trimethylsilyl)ethylhydroxylamine hydrochloride (376 mg, 2.22 mmol) was added. The ice bath was removed and the mixture was

-44-

stirred for 20 hours at 23 °C. The mixture was diluted with aqueous ammonium chloride and extracted with 1:1 ethyl acetate/diethyl ether (3 x). The combined organic extracts were washed with saturated aqueous sodium carbonate (2 x), water (1 x), and brine (1 x). The organic layer was dried (magnesium sulfate), filtered, and the filtrate was concentrated in vacuo. The residual yellow oil was purified by flash chromatography (eluting with 3:7 ethyl acetate/hexanes) to give 650 mg of 3-(S)-4-(4'-fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid (2-trimethylsilyl-ethoxy)-amide as a white foam. MS: 523 (M-1).

(c) A solution of 3-(S)-4-(4'-fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid (2-trimethylsilyl-ethoxy)-amide (650 mg, 1.24 mmol) in 8 mL of trifluoroacetic acid was stirred for at 22 °C for 16 hours. The mixture was concentrated in vacuo and the residue was triturated with methylene chloride and diethyl ether. The solvent was removed to give 550 mg of a tan solid. The solid was suspended in 1:1 diethyl ether/hexanes and stirred gently for 20 hours. The solids were collected by filtration (1:1 diethyl ether/hexanes rinsing) and dried to give 470 mg of 3-(S)-4-(4'-fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide as white solid. MS: 423 (M-1).

Example 8

3-(S)-4-[4-(4-Fluorobenzoyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide

(a) To a stirred, cold (0 °C) solution of the known (Belgian Patent Publication BE 893025) 2,2-dimethyl-thiomorpholine-3-carboxylic acid (600 mg, 3.42 mmol) in 10 mL of 1:1 water/dioxane was added 6 N sodium hydroxide (1.2 mL, 7.1 mmol). To the resulting solution 4-(4-fluorobenzoyloxy)benzenesulfonyl chloride (1.08 g, 3.77 mmol) was added. After 30 and 60 minutes an additional 1 gram of 4-(4-fluorobenzoyloxy)benzenesulfonyl chloride and 1.2 mL of 6 N sodium hydroxide was added. The mixture (pH ca. 12) was diluted with water and extracted with diethyl ether (1 x). The ethereal layer was washed with 1 N sodium hydroxide; the combined basic aqueous layers were acidified to pH 3 using concentrated hydrochloric acid, and the acidic mixture was extracted with ethyl acetate (3 x). The combined organic extracts were dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo to give 820 mg of 3-(S)-4-[4-(4-

-45-

fluorobenzoyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid as a white solid. MS: 438 (M-1).

(b) To a stirred, cold (0 °C) solution of 3-(S)-4-[4-(4-fluorobenzoyloxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid (820 mg, 1.87 mmol) in 5 mL of methylene chloride was added triethylamine (0.52 mL, 3.74 mmol) under a nitrogen atmosphere. Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (1.24 g, 2.81 mmol) was added and the resulting solution was stirred for 5 minutes before O-(tert-butyldimethylsilyl)hydroxylamine (550 mg, 3.74 mmol) was added. The ice bath was removed and the mixture was stirred for 16 hours at 23 °C. The mixture was diluted with aqueous ammonium chloride and extracted with ethyl acetate (3 x). The combined organic extracts were washed with water, brine, and dried over sodium sulfate. Filtration and concentration of the filtrate gave a viscous yellow oil, which was purified by flash chromatography (eluting with 1:3 ethyl acetate/hexanes) to give 270 mg of 3-(S)-4-[4-(4-fluorobenzoyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid (tert-butyldimethylsiloxy)-amide as a white foam. MS: 569 (M+1).

(c) To a stirred, cold (0 °C) solution of 3-(S)-4-[4-(4-fluorobenzoyloxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid (tert-butyldimethylsiloxy)-amide (270 mg, 0.47 mmol) in 10 mL of tetrahydrofuran was added two drops of concentrated hydrochloric acid. After 30 minutes the mixture was diluted with 15 mL of tetrahydrofuran and the mixture was concentrated in vacuo to a volume of ca. 5 mL. The volume was adjusted to ca. 25 mL with tetrahydrofuran and the mixture was concentrated again to ca. 5 mL. This process was repeated twice more before the mixture was finally concentrated to dryness. The resulting solids were suspended in a mixture of hexanes and diethyl ether and the mixture was stirred for 16 hours. The solid were collected by filtration, rinsed with diethyl ether, and dried to give 180 mg of 3-(S)-4-[4-(4-fluorobenzoyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxamide as a white solid. MS: 453 (M-1). ¹H NMR (400 MHz, dmso-d₆) δ 10.63 (s, 1 H), 8.80 (bs, 1 H) 7.59-7.61 (m, 2 H), 7.46-7.50 (m, 2 H), 7.17-7.21 (m, 2 H), 7.09-7.12 (m, 2 H), 5.12 (s, 2 H), 3.99 (s, 1 H), 3.87-3.93 (m, 1 H), 3.69 (d, 1 H, J = 12.7 Hz), 2.78-2.86 (m, 1 H), 2.44-2.50 (m, 1 H), 1.35 (s, 3 H), 1.12 (s, 3H).

Preparation 1

4-(4-Fluorobenzyloxy)benzenesulfonyl chloride

To a stirred solution of 4-hydroxybenzenesulfonic acid sodium salt dihydrate (5.13 g, 22.1 mmol) in 23 mL of 1 N sodium hydroxide was added a solution of 4-fluorobenzyl bromide (3.3 mL, 26.5 mmol) in 20 mL of ethanol. The mixture was heated at reflux for two days, then cooled to ambient temperature (22 °C), whereupon a white precipitate formed. The flaky white solids were collected by filtration, rinsed with ethyl acetate and diethyl ether, and dried to give 4.95 g of 4-(4-fluorobenzyloxy)-benzenesulfonic acid sodium salt. A stirred solution of 4-(4-fluorobenzyloxy)-benzenesulfonic acid sodium salt (13.0 g, 42.7 mmol) in 50 mL of thionyl chloride and two drops of dimethylformamide was heated at a gentle reflux for 8 hours. The mixture was concentrated to a yellow solid which was suspended in ethyl acetate and filtered. The filtrate was concentrated to 11.2 g of 4-(4-fluorobenzyloxy)benzenesulfonyl chloride as a light yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 7.95-7.98 (m, 2 H), 7.38-7.41 (m, 2 H), 7.08-7.12 (m, 4 H), 5.12 (s, 2 H).

Preparation 2

3-(4-Fluorophenoxy)propane-1-sulfonyl chloride

To a stirred solution of 4-fluorophenol (5.0 g, 44.6 mmol) in 50 mL of toluene was added sodium hydride (60% dispersion in mineral oil, 1.78 g, 44.6 mmol) at ambient temperature (22 °C). After 20 minutes, a solution of 1,3-propane sulfone (3.9 mL, 44.6 mmol) in toluene was added slowly and the mixture was stirred for 16 hours. The reaction was quenched by the addition of methanol and the mixture was concentrated in vacuo to an off-white solid. This solid was suspended in ethyl acetate, filtered, and the solids were collected and dried to give 10.9 g of 3-(4-fluorophenoxy)propane-1-sulfonic acid sodium salt as an off-white powder. A stirred solution of 3-(4-fluorophenoxy)propane-1-sulfonic acid sodium salt (2.0 g, 7.8 mmol) in 10 mL of thionyl chloride and one drop of dimethylformamide was heated at reflux for 16 hours. The mixture was then cooled to 0 °C, diluted with 25 mL of diethyl ether, and the reaction was quenched by the slow addition of water. The organic layer was removed and the aqueous layer was extracted with 25 mL of diethyl ether. The combined organic layers were washed with brine and dried over

-47-

sodium sulfate. Filtration and concentration gave 1.75 g of 3-(4-fluoro-phenoxy)-propane-1-sulfonyl chloride as a yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 6.96-7.00 (m, 2 H), 6.80-6.84 (m, 2 H), 4.10 (t, 2 H, $J = 5.5$ Hz), 3.91 (t, 2 H, $J = 7.5$ Hz) 2.47-2.54 (m, 2 H).

5


Preparation 3

4'-Fluorobiphenylsulfonyl chloride

Chlorosulfonic acid (8.7 mL, 0.13 mole) was added dropwise to stirred cold (0 °C) 4-fluorobiphenyl (10.2 g, 59 mmol). After 30 minutes at 0 °C the reaction mixture was poured onto ice. The resulting white precipitate was collected by
10 filtration and dissolved in chloroform. The chloroform solution was washed with water, brine, dried over magnesium sulfate, and concentrated to afford a white solid. The desired 4'-fluorobiphenylsulfonyl chloride (4.3 g), was separated from 4'-fluorobiphenylsulfonic acid by crystallization of the latter from ethyl acetate and crystallization of the remaining material from hexanes.

CLAIMS

1. A compound of the formula



or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

- 15 X is carbon, oxygen or sulfur;


Y is carbon, oxygen, sulfur, SO, SO₂ or nitrogen;

- R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are selected from the group consisting of hydrogen, (C₁-C₆)alkyl optionally substituted by one or two groups selected from (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, halo, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₂-C₉)heteroarylamino, (C₂-C₉)heteroarylthio, (C₂-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₈)cycloalkyl, hydroxy, piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₂-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkyl)₂amino; (C₂-C₉)alkenyl, (C₆-C₁₀)aryl(C₂-C₉)alkenyl, (C₂-C₉)heteroaryl(C₂-C₉)alkenyl, (C₂-C₉)alkynyl, (C₆-C₁₀)aryl(C₂-C₉)alkynyl, (C₂-C₉)heteroaryl(C₂-C₉)alkynyl, (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, perfluoro(C₁-C₆)alkyl, (C₆-C₁₀)aryl,
- 20
- 25

-49-

(C₂-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₂-C₉)heteroarylamino, (C₂-C₉)heteroarylthio, (C₂-C₉)heteroaryloxy, (C₃-C₈)cycloalkyl, (C₁-C₈)alkyl(hydroxymethylene), piperidyl, (C₁-C₈)alkylpiperidyl, (C₁-C₈)acylamino, (C₁-C₈)acylthio, (C₁-C₈)acyloxy, R¹⁰(C₁-C₈)alkyl or a group of the formula

5



10 wherein n is 0 to 6;


y is 0 or 1;

W is oxygen or >NR²⁴;


Z is -OR¹¹, -NR²⁴R¹¹, azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl,

15 tetrahydroisoquinolinyl or a bridged diazabicycloalkyl ring selected from the group consisting of


20



a




b




c

25

-50-



d



e

10 wherein r is 1, 2 or 3;

m is 1 or 2;

p is 0 or 1; and

V is hydrogen, (C₁-C₃)alkyl, (C₁-C₆)alkyl(C=O)-, (C₁-C₆)alkoxy(C=O)-, (C₆-C₁₀)aryl(C=O)-, (C₆-C₁₀)aryloxy(C=O)-, (C₆-C₁₀)aryl(C₁-C₆)alkyl(C=O)-, (C₆-C₁₀)aryl-
 15 (C₁-C₆)alkoxy(C=O)-, or (C₁-C₆)alkoxy(C=O)-O-;

wherein each heterocyclic group (i.e., each Z cyclic group containing one or more heteroatoms) may optionally be independently substituted by one or two groups selected from hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₁₀)acyl, (C₁-C₁₀)acyloxy, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₂-C₉)heteroaryl(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl, (C₁-C₆)acyloxy(C₁-C₆)alkyl, (C₁-C₆)alkylthio, (C₁-C₆)alkylthio(C₁-C₆)alkyl, (C₆-C₁₀)arylthio, (C₆-C₁₀)arylthio(C₁-C₆)alkyl, R¹²R¹³N-, R¹²R¹³NSO₂-, R¹²R¹³N(C=O)-, R¹²R¹³N(C=O)-(C₁-C₆)alkyl, R¹⁴SO₂-, R¹⁴SO₂NH-, R¹⁵(C=O)-[N(R¹²)]-, R¹⁶O(C=O)-, or R¹⁶O(C=O)-(C₁-C₆)alkyl;

25 wherein R¹⁰ is (C₁-C₆)acylpiperazinyl, (C₆-C₁₀)arylpiperazinyl, (C₂-C₉)heteroarylpiperazinyl, (C₁-C₆)alkylpiperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkylpiperazinyl, (C₂-C₉)heteroaryl(C₁-C₆)alkylpiperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl,

piperidyl, (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)arylpiperidyl, (C₂-C₉)heteroarylpiperidyl, (C₁-C₆)alkylpiperidyl(C₁-C₆)alkyl, (C₆-C₁₀)arylpiperidyl(C₁-C₆)alkyl, (C₂-C₉)heteroaryl-piperidyl-(C₁-C₆)alkyl or (C₁-C₆)acylpiperidyl;

R¹¹ is hydrogen, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₂-C₉)heteroaryl(C₁-C₆)alkyl, (C₁-C₆)alkyl(C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₆)alkyl(C₂-C₉)heteroaryl(C₁-C₆)alkyl, 5-indanyl, -CHR¹⁷O-(C=O)-R¹⁸ or -CH₂(C=O)-NR¹⁹R²⁰;

R¹² and R¹³ are each independently hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl or (C₂-C₉)heteroaryl(C₁-C₆)alkyl or R¹² and R¹³ may be taken together with the nitrogen to which they are attached to form an azetidiny, pyrrolidiny, piperidiny, morpholiny or thiomorpholiny ring;

R¹⁴ is trifluoromethyl, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl or (C₂-C₉)heteroaryl(C₁-C₆)alkyl;

R¹⁵ is hydrogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, (C₁-C₆)aryl(C₁-C₆)alkyl(C₆-C₁₀)aryl(C₁-C₆)alkoxy or (C₂-C₉)heteroaryl(C₁-C₆)alkyl;

R¹⁶ is (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₂-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, 5-indanyl, -[CH(R¹⁷)]O-(C=O)-R¹⁸, -CH₂(C=O)-NR¹⁹R²⁰, or R²¹O(C₁-C₆)alkyl;

R¹⁷ is hydrogen or (C₁-C₆)alkyl;

R¹⁸ is (C₁-C₆)alkyl, (C₁-C₆)alkoxy or (C₆-C₁₀)aryl;

R¹⁹ and R²⁰ are each independently hydrogen or (C₁-C₆)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidiny, pyrrolidiny, piperidiny, morpholiny or thiomorpholiny ring;

R²¹ is H₂N(CHR²²)(C=O)-;

R²² is the side chain of a natural D- or L-amino acid;


R²³ is hydrogen, (C₁-C₆)acyl, (C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₂-C₉)heteroaryl(C₁-C₆)alkyl or (C₁-C₆)alkylsulfonyl;

R²⁴ wherever it occurs is independently hydrogen or (C₁-C₆)alkyl;

or R¹ and R², or R³ and R⁴, or R⁵ and R⁶ may be taken together to form a carbonyl;

or R¹ and R², or R³ and R⁴, or R⁵ and R⁶, or R⁷ and R⁸ may be taken together to form a (C₃-C₆)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula

5



Q is (C₁-C₁₀)alkyl, (C₆-C₁₀)aryl, (C₆-C₁₀)aryloxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)alkyl, (C₆-C₁₀)aryloxy(C₂-C₉)heteroaryl, (C₂-C₉)heteroaryl, (C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₂-C₉)heteroaryloxy(C₆-C₁₀)aryl, (C₁-C₆)alkyl(C₂-C₉)heteroaryl, (C₁-C₆)alkoxy(C₂-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₂-C₉)heteroaryl, (C₂-C₉)heteroaryloxy(C₂-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₁-C₆)alkyl, (C₂-C₉)heteroaryloxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(C₆-C₁₀)aryloxy(C₆-C₁₀)aryl, (C₁-C₆)alkyl(C₂-C₉)heteroaryloxy(C₆-C₁₀)aryl, (C₁-C₆)alkoxy(C₆-C₁₀)aryloxy(C₆-C₁₀)aryl, (C₁-C₆)alkoxy(C₂-C₉)heteroaryloxy(C₆-C₁₀)aryl or (C₁-C₆)alkoxy(C₆-C₁₀)aryloxy(C₂-C₉)heteroaryl optionally substituted by fluoro, chloro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy or perfluoro(C₁-C₃)alkyl;

with the proviso that when y is zero, Q is other than (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl or (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)heteroaryl, and anyone of R¹-R⁹ is a group of formula II then Z must be substituted when defined as azetidiny, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl, (C₁-C₁₀)acylpiperazinyl, (C₁-C₆)alkylpiperazinyl, (C₆-C₁₀)arylpiperazinyl, (C₂-C₉)heteroarylpiperazinyl or a bridged diazabicycloalkyl ring;

with the proviso that when y is zero, Q is other than (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl or (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)heteroaryl, then at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ must be defined as the group of formula II;

with the proviso that when Q is (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl or (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)heteroaryl, then R¹-R⁹ may be other than formula II but when R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are all defined by hydrogen or (C₁-C₆)alkyl, either X or Y is oxygen, sulfur, SO, -SO₂- or nitrogen, or the broken line represents a double bond;

with the proviso that R⁷ is other than hydrogen only when R⁸ is other than hydrogen;

with the proviso that R⁹ is other than hydrogen only when R⁵ is other than hydrogen;

with the proviso that R³ is other than hydrogen only when R⁴ is other than hydrogen;

with the proviso that R² is other than hydrogen only when R¹ is other than hydrogen;

with the proviso that when R¹, R² and R⁹ are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions of the ring;

with the proviso that when X is nitrogen, R⁴ is not present;

with the proviso that when X is oxygen, sulfur, SO, SO₂ or nitrogen and when one or more of the group consisting of R¹, R², R⁵ and R⁶, is a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 4- or 6- positions;

with the proviso that when Y is oxygen, sulfur, SO, SO₂ or nitrogen and when one or more of the group consisting of R³, R⁴, R⁷ and R⁸, are independently a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 3- or 5- positions;

with the proviso that when X is oxygen, sulfur, SO or SO₂, R³ and R⁴ are not present;

with the proviso that when y is 1 and W is NR²⁴ or oxygen, Z cannot be hydroxy;

with the proviso that when Y is oxygen, sulfur, SO or SO₂, R⁵ and R⁶ are not present;

with the proviso that when Y is nitrogen, R⁶ is not present;

with the proviso that when the broken line represents a double bond, R⁴ and
5 R⁶ are not present;

with the proviso that when R³ and R⁵ are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y;

with the proviso that when either the X or Y position is oxygen, sulfur, SO,
10 SO₂ or nitrogen, the other of X or Y is carbon;

with the proviso that when X or Y is defined by a heteroatom, the broken line does not represent a double bond.

2. A compound according to claim 1, wherein Y is carbon, SO, SO₂, or oxygen.

15 3. A compound according to claim 1, wherein Q is (C₆-C₁₀)aryl-(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₂-C₆)heteroaryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, or (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)alkyl wherein each terminal aryl group is optionally substituted by fluoro.

4. A compound according to claim 1, wherein R², R³, R⁶, R⁷ and R⁹ are
20 hydrogen.

5. A compound according to claim 1, wherein Y is carbon; Q is (C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, or (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)alkyl.

6. A compound according to claim 1, wherein Y is oxygen, sulfur, SO, or
25 SO₂.

7. A compound according to claim 3, wherein Y is oxygen, sulfur, SO or SO₂.

8. A compound according to claim 1, wherein at least one of R^7 - R^9 is other than hydrogen.
9. A compound according to claim 3, wherein at least one of R^7 - R^9 is other than hydrogen.
- 5 10. A compound according to claim 6, wherein at least one of R^7 - R^9 is other than hydrogen.
11. A compound according to claim 7, wherein at least one of R^7 - R^9 is other than hydrogen.
12. A compound according to claim 1, wherein at least one of R^7 - R^9 is
10 (C_1-C_8) alkyl.
13. A compound according to claim 3, wherein at least one of R^7 - R^9 is (C_1-C_8) alkyl.
14. A compound according to claim 6, wherein at least one of R^7 - R^9 is (C_1-C_8) alkyl.
- 15 15. A compound according to claim 7, wherein at least one of R^7 - R^9 is (C_1-C_8) alkyl.
16. A compound according to claim 1, wherein at least one of R^7 - R^9 is methyl.
17. A compound according to claim 3, wherein at least one of R^7 - R^9 is
20 methyl.
18. A compound according to claim 6, wherein at least one of R^7 - R^9 is methyl.
19. A compound according to claim 7, wherein at least one of R^7 - R^9 is methyl.
- 25 20. A compound according to claim 1, wherein R^7 and R^8 are taken together to form a carbonyl and R^9 is (C_1-C_8) alkyl.
21. A compound according to claim 3, wherein R^7 and R^8 are taken together to form a carbonyl and R^9 is (C_1-C_8) alkyl.

22. A compound according to claim 6, wherein R^7 and R^8 are taken together to form a carbonyl and R^9 is (C_1-C_6) alkyl.
23. A compound according to claim 7, wherein R^7 and R^8 are taken together to form a carbonyl and R^9 is (C_1-C_6) alkyl.
- 5 24. A compound according to claim 1 wherein R^7 and R^8 are each methyl.
25. A compound according to claim 3 wherein R^7 and R^8 are each methyl.
26. A compound according to claim 6 wherein R^7 and R^8 are each methyl.
27. A compound according to claim 7 wherein R^7 and R^8 are each methyl.
28. A compound according to claim 1 wherein R^7 and R^8 are taken
10 together to form a (C_3-C_6) cycloalkyl group.
29. A compound according to claim 3 wherein R^7 and R^8 are taken together to form a (C_3-C_6) cycloalkyl group.
30. A compound according to claim 6 wherein R^7 and R^8 are taken together to form a (C_3-C_6) cycloalkyl group.
- 15 31. A compound according to claim 8 wherein R^7 and R^8 are taken together to form a (C_3-C_6) cycloalkyl group.
32. A compound according to claim 1, wherein said compound is selected from the group consisting of:
- 20 (2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid;
- (2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester;
- (2R,4R)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid;
- 25 (2R,4R)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester;

(2R,3S)-{1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl}-carbamic acid isopropyl ester;

3-(S)-4-(4'-Fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

5 3-(S)-4-[4-(4-Fluorobenzyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;

(2R,4S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide; and

10 (2R,4R)-1-(4-Methoxybenzenesulfonyl)-4-(piperazine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide hydrochloride.

33. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, mucular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID'S and analgesics and in combination with
15 cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of claim 1 effective in
20 such treatment and a pharmaceutically acceptable carrier.

34. A method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of claim 1.

25 35. A method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, compounds of formula I may be used in combination with standard NSAID'S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix
30 metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human,

-58-

comprising administering to said mammal an amount of a compound of claim 1,
effective in treating such a condition.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/00064

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D211/62 C07D241/24 C07D279/12 C07D211/60 C07D211/90
A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 33172 A (PFIZER INC) 24 October 1996 see the whole document -----	1-33

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 April 1998

Date of mailing of the international search report

11. 05. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 98/00064

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 34-35
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 34-35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 98/00064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9633172 A	24-10-96	AU 5080296 A	31-10-96
		CN 1140165 A	15-01-97
		CZ 9601130 A	13-11-96
		EP 0821671 A	04-02-98
		FI 973974 A	16-10-97
		NO 961585 A	21-10-96
		SG 43350 A	17-10-97
<hr/>			